Why cell line screening is crucial for successful complement-dependent cytotoxicity (CDC) assay development

One of the major improvements in oncotherapy of late has been the development of monoclonal antibodies (mAbs) targeting tumor-specific antigens. The ability of these antibodies to kill tumor cells is largely dependent on their Fc effector function. While the complementarity-determining region of the molecule binds the specific tumor antigen, the Fc portion induces target-cell killing by three main mechanisms: complement-dependent cytotoxicity (CDC), antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP). Fc effector functionality is a critical area to assess for mAb therapeutics, and cell-based potency assays are used for QC batch release and biological characterization.

Setting the foundation of success in your drug development

The primary function of biopharmaceutical development is to demonstrate that the investigational drug is both safe and efficacious for human use. And aspect of this is to have a comprehensive understanding of both the drug substance and drug product, both from a physiochemical and biological viewpoint. Accordingly, there is a regulatory expectation that any investigational biopharmaceutical will be thoroughly characterized using a wide range of analytical techniques. Due to the highly complex nature of biopharmaceuticals, this is not a trivial exercise, often involving orthogonal analytical techniques to gain deep understanding of the biopharmaceutical product. In this brochure, we outline the regulatory expectations for biopharmaceutical characterization along with the specific requirements for some of the more common modalities that are currently in development.

Labcorp Launches H5 Bird Flu Test in the U.S., Now Available for Order through Physicians

New test supports public health preparedness efforts and testing infrastructure amid multistate outbreak of H5 bird flu in poultry and dairy cows BURLINGTON, N.C. , Dec. 17, 2024 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today

On-demand webinar: Developing predictive cancer models and more persistent CAR T-cell therapies through enhanced metabolic fitness

Identifying and treating inflammatory bowel disease

The first week of December marks Chron’s and Colitis Awareness Week. This is when we annually observe and raise awareness for the approximately 3 million people living with inflammatory bowel disease (IBD), the collective term for Crohn’s disease and colitis. Chron’s disease is inflammation of the gastrointestinal tract anywhere from the mouth to the anus, while colitis is inflammation of the colon/large intestine. Both conditions attack the digestive system and are medically incurable, but they can be managed to lessen their impact. 

Labcorp To Acquire Select Assets of MAWD Pathology Group

BURLINGTON, N.C., (Dec. 16, 2024) — Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, has entered into an agreement with MAWD Pathology Group in Lenexa, Kansas, to acquire select assets of the independent laboratory’s clinical and women’s health testing businesses.

The Future of Lab Medicine

 

Tune in as Dr. Mahul Amin discusses the evolving landscape of diagnostic testing, the impact of lab medicine on health systems, and future innovations that promise to shape the field, providing valuable insights for healthcare leaders.

Labcorp Finalizes Acquisition of Select Outreach Services From Ballad Health

JOHNSON CITY, Tenn. and BURLINGTON, NC, (Dec. 11, 2024) - Labcorp, a global leader of innovative and comprehensive laboratory services, announces it has finalized its acquisition of select outreach laboratory services from Ballad Health. 

Simplifying and advancing workplace drug testing with oral fluid

The landscape of workplace drug testing is evolving, with oral fluid testing at the forefront of this evolution. As the U.S. Department of Transportation (DOT) and other federal agencies approve an oral drug test for regulated programs, employers will soon have a new tool at their disposal for maintaining safe and drug-free workplaces. Here’s what you need to know.

Julia Wang

Julia Wang has served as Executive Vice President and Chief Financial Officer of Labcorp since December 2024.

Prior to joining Labcorp, Julia served as CFO of BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235) since 2021, which she joined in 2020 as Senior Vice President, Enterprise Optimization and Deputy CFO. While at BeiGene, she was instrumental in driving business transformations through accelerating growth, nurturing innovation and cultivating a culture of sustainable operating efficiencies.